Iloprost

Iloprost, the active ingredient in Iloprost, is a prostacyclin analog presented as a sterile solution for injection for intravenous use. It is indicated for the management of pulmonary arterial hypertension and for the treatment of digital ulcers associated with systemic sclerosis.

GNH USA supplies Iloprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. All batches are manufactured under GMP conditions and undergo rigorous quality testing before release.

Iloprost is a prostacyclin analog used in vascular disorders that affect the pulmonary circulation and peripheral microvasculature.

- Pulmonary arterial hypertension: improves exercise capacity and reduces pulmonary vascular resistance. - Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation. - Pulmonary hypertension (general): provides vasodilation to lower pulmonary arterial pressure.

Adverse reactions may occur with Iloprost therapy.

Common Side Effects: - Headache - Flushing - Nausea - Hypotension

Serious or Rare Side Effects: - Pulmonary edema - Severe hypotension - Bleeding complications

Use Iloprost with careful clinical monitoring.

- Monitor blood pressure: check regularly for hypotension. - Assess bleeding risk: avoid in patients with active hemorrhage. - Use caution in renal impairment: adjust monitoring as needed. - Avoid use in pregnancy: safety not established. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost may interact with other medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Epoprostenol: additive vasodilatory effect leading to severe hypotension.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance hypotensive effect. - Beta‑blockers: may mask tachycardia. - Diuretics: may exacerbate hypotension.